Arch Ophthalmol (Chicago Ill 1960) (2007) 125(12):16526
These results imply that the anti-inflammatory and potentially anti-atherosclerotic effects of GLP-1 RAs are not attributable to improved adiposity, which is often associated with a low-grade inflammation [87]
Around the same time, I think you remember that all of pharma was interested in obesity in the early 90s, everyone wanted to do diabetes as well as obesity, but they were separate teams and they all wanted to do small molecules, but it just happens to be so that the best idea we could find at that time was actually GLP-1, because we actually had clinical data relatively early that GLP-1 was a really good candidate as a treatment for diabetes because of the glucose sensitivity of the actions
Discreet, effective care is just one step away
Melanotan-1, also known as afamelanotide (marketed as Scenesse), is a linear 13-amino acid peptide that preferentially activates the MC1R receptor